Lake Street Capital Markets LLC

11/18/2026 | Press release | Distributed by Public on 11/18/2026 13:27

AbCellera Biologics Inc. (ABCL) - Initiation of Coverage

Lake Street Capital Markets Analyst, Daniel Brims, Ph.D., initiated coverage of AbCellera Biologics, Inc. with a BUY rating and price target of $19 (ABCL-$19). AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

‍

Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!
NameEmail Address
Thanks for joining our mailing list.
Oops! Something went wrong while submitting the form.
Attachment
Lake Street Capital Markets LLC published this content on November 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 18, 2026 at 19:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]